retatrutide expanded access program eli lilly gave extraordinary obesity drug to a 79-year-old patient. Who was it? Eli Lilly's retatrutide cuts weight

Additionally, some dermatologists are finding success with treating psoriasis and hidradenitis suppurativa with GLP-1s independent of an impact on weight loss

VNS is an emerging neuroregulatory treatment that, by modulating gut microbiota, improving insulin resistance, reducing inflammation, and regulating hormone levels, may provide a new therapeutic approach for PCOS and its associated metabolic abnormalities (104)

Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program

BMC Genomics 17, 312

There are no large human trials published yet

The primary pharmacodynamic distinctions between long-acting and short-acting GLP-1RAs are that long-acting agonists augment insulin production and suppress glucagon generation to lower postprandial glucose and fasting plasma glucose, while short-acting agonists chiefly lower postprandial glucose by delaying gastric emptying